Propanc Biopharma (PPCB) Intangibles (2011 - 2012)

Propanc Biopharma (PPCB) posted quarterly Intangibles of $27016.0 for Q1 2012, up 2.07% quarter-over-quarter from $26468.0 in Q4 2011.

Propanc Biopharma (PPCB) Intangibles (2011 - 2012) Analysis & Trends

Propanc Biopharma (PPCB) has reported Intangibles for 2 consecutive years, with $27016.0 the latest figure, recorded in Q1 2012.

In Q1 2012, Intangibles changed N/A year-over-year to $27016.0; the TTM figure through Mar 2012 stood at $27016.0 (changed N/A YoY), while the FY2011 annual figure was $27563.0, changed N/A from the prior year.
Intangibles climbed to $27016.0 in Q1 2012 per PPCB's latest filing, from $26468.0 in the prior quarter.
Across five years, Intangibles topped out at $27563.0 in Q2 2011 and bottomed at $26468.0 in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	266.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	93.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Propanc Biopharma	587,855.41	587,855.41	-	-

Download Data